Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Kaelin, 2004, The von Hippel-Lindau tumor suppressor gene and kidney cancer, Clin Cancer Res, 10, 6290, 10.1158/1078-0432.CCR-sup-040025 Brugarolas, 2007, Renal cell carcinoma—molecular pathways and therapies, N Engl J Med, 356, 185, 10.1056/NEJMe068263 Brugarolas, 2003, TSC2 regulates VEGF through mTOR-dependent and -independent pathways, Cancer Cell, 4, 147, 10.1016/S1535-6108(03)00187-9 Thomas, 2006, Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer, Nat Med, 12, 122, 10.1038/nm1337 Motzer, 1996, Renal cell carcinoma, N Engl J Med, 335, 865, 10.1056/NEJM199609193351207 Coppin, 2004, Immunotherapy for advanced renal cell cancer, Cochrane Database Syst Rev, 3, 10.1002/14651858.CD001425.pub2 Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Escudier, 2007, Sorafenib in advanced clear-cell renal cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 Hudes, 2007, Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma, N Engl J Med, 356, 2271, 10.1056/NEJMoa066838 Escudier, 2007, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, Lancet, 370, 2103, 10.1016/S0140-6736(07)61904-7 Coppin, 2008, Targeted therapy for advanced renal cell carcinoma, Cochrane Database Syst Rev, 2 Jac, 2007, A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC), J Clin Oncol, 25, 261S O'Donnell, 2008, Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors, J Clin Oncol, 26, 1588, 10.1200/JCO.2007.14.0988 Tabernero, 2008, Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors, J Clin Oncol, 26, 1603, 10.1200/JCO.2007.14.5482 Tanaka, 2008, Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data, J Clin Oncol, 26, 1596, 10.1200/JCO.2007.14.1127 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Motzer, 2004, Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma, J Clin Oncol, 22, 454, 10.1200/JCO.2004.06.132 Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365 Cella, 2007, Development and validation of a scale to measure disease-related symptoms of kidney cancer, Value Health, 10, 285, 10.1111/j.1524-4733.2007.00183.x Lan, 1983, Discrete sequential boundaries for clinical trials, Biometrika, 70, 659, 10.2307/2336502 O'Brien, 1979, A multiple testing procedure for clinical trials, Biometrics, 35, 549, 10.2307/2530245 Johnson, 2003, End points and United States Food and Drug Administration approval of oncology drugs, J Clin Oncol, 21, 1404, 10.1200/JCO.2003.08.072 Amato, 2006, A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC), J Clin Oncol, 24 Atkins, 2004, Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma, J Clin Oncol, 22, 909, 10.1200/JCO.2004.08.185